IgA Nephropathy Pipeline to Witness Various Collab
Post# of 301275
NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- According to a new research report “IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, IgA nephropathy currently exhibits a pipeline with 12 drug candidates.
Browse Report Description at: https://www.psmarketresearch.com/market-analy...e-analysis
The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates in different stages of development. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.
Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine.
The research finds that different companies have collaborated for the development of IgA nephropathy pipeline. In October 2012, Pharmalink AB entered into a contract with Patheon Inc. for manufacturing of Nefecon.
Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.
Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry...e-analysis
Related Research
T-Cell Immunotherapy Pipeline Analysis
TILs, defined by NCI, the U.S. federal government's principal agency for cancer research and training, as a preparation of cells consisting of autologous tumor infiltrating lymphocytes, that are manipulated in vitro and, upon administration in vivo, re-infiltrate the tumor to initiate tumor cell lysis. In vitro, TILs are isolated from tumor tissue and cultured with lymphokines such as interleukin-2. The therapeutic TILs are then infused into patients, where after re-infiltration of the tumor, they may induce lysis of tumor cells and tumor regression. The use of therapeutic TILs is considered as an adoptive immunotherapy.
https://www.psmarketresearch.com/market-analy...e-analysis
Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis
Bronchoscopy and surgical lung biopsy are used as testing procedures. In Bronchoscopy, lymphocytosis in bronchoalveolar lavage fluid is absent which is observed for the diagnosis. The best sample for characteristic usual interstitial pneumonia from other idiopathic interstitial pneumonias is surgical lung biopsy. The treatment for IPF as optimal medical cure has yet to be identified. This creates ample growth opportunities for pharmaceutical companies, as there is very low competition due to lack of approved drugs.
https://www.psmarketresearch.com/market-analy...ics-market
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact: Kundan Kumar Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-free: +1-888-778-7886 (USA/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com
(0)
(0)